Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

Preclinical evaluation of combined RRM2/DNA damage response signaling as therapy for high-risk neuroblastoma and potential entry point for sensitization to immune checkpoint inhibition.

Outputs and Outcomes

Code

DOCT/002598

Duration

21 February 2022 → 21 September 2025 (Ongoing)

Doctoral researcher

Iris Nelen

Research disciplines

No data available

Project description

No data available